The first prescription for a medication for a rare condition in a hospital was written by a doctor in Africa, according to a new report.
The first prescription is for a powerful anti-inflammatory drug called Dacron, commonly used to treat a variety of conditions, including heartburn, high blood pressure, and psoriasis.
The prescription is from a doctor who lives in the United States, and is not a doctor.
It’s the first time a prescription for the drug has been made by a U.S. doctor to be printed in the medical literature, said Katherine Cogdell, an associate professor at the University of Minnesota School of Medicine and a specialist in infectious diseases.
The report, published in the New England Journal of Medicine, was conducted by Cogsons team of researchers from the University at Buffalo and the Mayo Clinic in Minnesota.
They reviewed the records of more than 100,000 people who had prescriptions for the anti-inflammatories in the past two decades.
“The idea is that we are starting to get this kind of data that allows us to look at the drug’s effectiveness,” said Cogdam.
She said she and her colleagues were surprised to find that there were nearly 200,000 prescriptions written in the U.K. for the same drug, but only 10,000 in the world.
“This is a huge change in the prescription process, and it’s really exciting,” said Dr. Mark Ehrlich, director of the Center for Infectious Disease Epidemiology and Prevention at the Mayo Institute for Infection Control and Prevention.
The drug is used in several countries including Africa, but not the U, and has been in development for decades.
It is widely used to fight infections in people with heartburn and psoriatic arthritis, as well as psorinitis and ulcerative colitis.
“There is no known mechanism by which this drug can reduce the incidence of the disease,” the report said.
Cogdam and her team found that about 3% of people in the UK had prescriptions filled for the drugs, but that about 2.5% of those patients were prescribed for the conditions, a figure that is similar to other countries.
“We do not know why that occurs,” said Ehrich.
He said this difference may be due to how the drugs are marketed.In the U